Stockscreener 앱 받기
45.68
8.20%
3.46
시간 외 거래:
45.99
0.31
+0.68%
전일 마감가:
$42.22
열려 있는:
$42.93
하루 거래량:
666.40K
Relative Volume:
0.89
시가총액:
$3.59B
수익:
$688.00K
순이익/손실:
$-135.82M
주가수익비율:
-21.98
EPS:
-2.078
순현금흐름:
$-169.41M
1주 성능:
+6.08%
1개월 성능:
+4.10%
6개월 성능:
+192.63%
1년 성능:
+151.54%
1일 변동 폭
$42.68
$45.79
1주일 범위
$40.91
$45.79
52주 변동 폭
$10.91
$45.79
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
45.68 | 3.32B | 688.00K | -135.82M | -169.41M | -2.078 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month HighHere's What Happened - MarketBeat
Spyre Therapeutics stock hits 52-week high at 45.79 USD By Investing.com - Investing.com UK
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio - Yahoo Finance
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst - The Globe and Mail
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline - TipRanks
SYRE Technical Analysis | Trend, Signals & Chart Patterns | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
US Market Recap: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - AOL.com
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means - The Motley Fool
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares - Intellectia AI
VR Adviser Increases Spyre Therapeutics Investment to $120.74MNews and Statistics - IndexBox
Signal or Noise: How VR Adviser's Acquisition of Spyre Therapeutics Impacts Fools - Bitget
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - The Motley Fool
SYRE Stock Gets a Boost: Stifel Raises Price Target to $92 | SYR - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $92.00 - MarketBeat
Stifel raises Spyre stock price target to $92 on TL1A potential - Investing.com Canada
Guggenheim Sticks to Its Buy Rating for Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE) - Seeking Alpha
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC TimelineHas The Bull Case Changed? - simplywall.st
BTIG Reiterates Buy Rating for Spyre Therapeutics (SYRE) with $7 - GuruFocus
Spyre Therapeutics (SYRE) Advances RA Sub-Study with Early Resul - GuruFocus
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026 - Meyka
Deutsche Bank Raises Price Target for Spyre Therapeutics on Strong Cash Position - timothysykes.com
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 9.3%Should You Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Given Buy Rating at BTIG Research - MarketBeat
Leerink reiterates Spyre stock Outperform on faster trial timeline By Investing.com - Investing.com Canada
Spyre Therapeutics stock remains top 2026 pick at Guggenheim By Investing.com - Investing.com Canada
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 - Bitget
RA sub-study patient enrollment ends in Phase 2 SKYWAY trial as Spyre Therapeutics, Inc. eyes data release - Traders Union
Spyre Therapeutics, Inc. $SYRE Shares Acquired by HighVista Strategies LLC - MarketBeat
Aug Spikes: Can Spyre Therapeutics Inc lead its sector in growthRate Cut & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Baker BROS. Advisors LP Buys 373,297 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - AOL.com
Transcript : Spyre Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
Market Review: Is RBNE stock risky to hold now2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Weekly Earnings: What is the implied volatility of Spyre Therapeutics IncMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Patterns Watch: Can Spyre Therapeutics Inc grow without external fundingMarket Trend Review & Technical Confirmation Trade Alerts - baoquankhu1.vn
Trading Recap: Can Spyre Therapeutics Inc deliver consistent EPS growthVolume Spike & Weekly Top Performers Watchlists - baoquankhu1.vn
New Spyre hires get 46,600 stock options at $42.49 strike - Stock Titan
[EFFECT] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns - Yahoo Finance
Insider Selling: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
Investment Review: Is Spyre Therapeutics Inc a top pick in the sectorPortfolio Return Report & Verified Entry Point Signals - baoquankhu1.vn
Spyre Therapeutics CEO Sells 15,000 Shares - TradingView
Support Test: Can Spyre Therapeutics Inc lead its sector in growthPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):